Recent Hodgkin's Lymphoma News

Duration of Blood Storage Does Not Affect Outcomes for Patients Requiring Blood Transfusions (December 1, 2016)

The length of time that blood is stored prior to a blood transfusion, within normal ranges, does not appear to affect mortality among patients requiring transfusions. These results were recently published... Continue Reading

CAR Therapy Effective in Advanced Lymphoma (June 20, 2016)

According to results of several presentations at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO), chimeric antigen receptor (CAR) therapies appear to have significant anti-cancer... Continue Reading

Defitelio® Approved for Life-Threatening Complication of Stem Cell Transplant (March 30, 2016)

The United States Food and Drug Administration (FDA) has approved Defitelio® (defibrotide sodium) for the treatment of hepatic veno-occlusive disease (VOD) following a stem cell transplant. Defitelio... Continue Reading

ADCETRIS® Provides High-Activity as Initial Therapy in Elderly with Hodgkin’s Lymphoma (October 6, 2015)

The agent, ADCETRIS® (brentuximab vedotin), provides high anti-cancer activity as initial therapy in elderly patients who might not be able to tolerate standard therapy for treatment of Hodgkin’s lymphoma.... Continue Reading

Adcetris® after Stem Cell Transplant Improves Survival in Hodgkin’s Lymphoma (April 28, 2015)

For patients with relapsed or refractory Hodgkin’s lymphoma (HL), treatment with Adcetris® (brentuximab vedotin) after autologous stem cell transplant may improve survival. The Lancet published these... Continue Reading

Keytruda PD-1 Immunotherapy Shows Promise in Hodgkin’s Lymphoma (December 23, 2014)

The cancer immunotherapy strategy known as programmed cell death 1 (PD-1) has generated great excitement for its ability to help the immune system recognize and attack cancer. Now according to researchers... Continue Reading

PD-1 Immunotherapy Shows Promise in Hodgkin’s Lymphoma (December 18, 2014)

The cancer immunotherapy strategy known as programmed cell death 1 (PD-1) has generated great excitement for its ability to help the immune system recognize and attack cancer. Now according to researcher... Continue Reading

Post-Transplant Adcetris® Improves Treatment of Hodgkin’s Lymphoma and is Likely to Become New Standard of Care (December 12, 2014)

The use of post stem cell transplant (SCT) maintenance therapy with Adcetris® (brentuximab vedotin) significantly improved progression-free survival in Hodgkin’s Lymphoma (HL) according to the results... Continue Reading

Radiation Therapy Improves 10-Year Survival for Patients With Early Hodgkin’s Lymphoma (October 30, 2014)

According to a large observational study based on the National Cancer Database (NCDB), adding consolidation radiation therapy to chemotherapy significantly improves 10-year survival in patients with stage... Continue Reading

Rituxan Active in Nodular Lymphocyte-Predominant Hodgkin’s Lymphoma (February 26, 2014)

Rituxan® (rituximab) was active in previously treated and untreated patients with nodular lymphocyte–predominant Hodgkin lymphoma, according to the results of a phase II study published in the Journal... Continue Reading

Next Page »